Our second petition, for which we will be joined by witnesses remotely, is PE1950, on ensuring that immunosuppressed people in Scotland can access the Evusheld antibody treatment. The petition, which was lodged by Alex Marshall, calls on the Scottish Parliament to urge the Scottish Government to enable access, via the national health service, to the Evusheld prophylactic treatment for people who have a zero or weak response to the Covid-19 vaccines.
We previously considered the petition at our meeting on 9 November, when we agreed to write to various organisations and to invite the petitioner and representatives from the patient campaign group, Evusheld for the UK, to provide evidence to the committee. Members will have noted in our papers for today’s meeting that the petitioner, Alex Marshall, has declined the opportunity to provide evidence or pursue the petition further, as he feels that the emergence of new Covid-19 variants has rendered the Evusheld treatment ineffective.
I note that the committee has now received responses from the Scottish Medicines Consortium, Immunodeficiency UK, Blood Cancer UK and Kidney Research UK.
Despite the unusual circumstances in which we find ourselves and the fact that the pandemic has moved on, there are issues that the committee wishes to explore. I am pleased to welcome Mark Oakley and Nikola Brigden, who are from Evusheld for the UK. Good morning to you both.
We move straight to questions. Please raise a hand or put an R in the chat function—that is the usual way. The clerks are monitoring that and will ensure that we know when you would like to come in and contribute. I move straight to my colleague David Torrance.
10:15
